Viewing nowCombinationOlmesartan Medoxomil and Amlodipine Tablet 10/40 Milligrams
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Withus Pharmaceutical Co., Ltd.

MFDS item code 202001262 · Approved 2020.02.21
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension who have difficulty controlling blood pressure with either amlodipine or olmesartan medoxomil monotherapy. It effectively lowers blood pressure and helps reduce the risk of cardiovascular complications. Therefore, this medication is used for the treatment of essential hypertension.
Administer 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, ‘Patients who must not receive this medicine,’ under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored closely and more frequently in older adults.
Safety and efficacy have not been established in pediatric patients younger than 18 years.
This medication can cause serious harm to the fetus and neonate if taken during the second and third trimesters of pregnancy and should be discontinued immediately upon confirmation of pregnancy. It should not be administered to those who are allergic to the active ingredients, women who are pregnant or breastfeeding, patients with severe liver disease or aortic stenosis, patients with biliary obstruction, patients undergoing dialysis, patients in shock, or certain diabetic patients. Patients with a deficiency of fluids or sodium may experience hypotension; therefore, they should be closely monitored when starting this medication, and appropriate measures should be taken if hypotension occurs. Due to the vasodilatory effect, acute hypotension may rarely occur, so particular caution is necessary for patients with heart valve abnormalities or severe heart disease. Patients with impaired kidney function or heart failure may experience worsened renal function when taking this medication, so regular testing is needed. This medication can cause electrolyte imbalances, such as hyperkalemia, so blood tests should confirm the status when taken with drugs that may increase potassium levels. Taking this medication during pregnancy poses a risk of fetal damage; therefore, individuals planning or confirming pregnancy should consult their doctor before deciding to take this medication. During breastfeeding, there is a possibility that this medication may be transferred to breast milk, causing adverse reactions in infants. Therefore, it is recommended to either discontinue breastfeeding or stop taking the medication. This medication is not recommended for children under 18 years of age, as its safety and efficacy have not been established. Elderly patients should start at a low dose considering diminished kidney and liver function and comorbid conditions, and should take it cautiously. In cases of overdose, hypotension and cardiac arrhythmias may occur, requiring immediate hospital treatment, where cardiac and respiratory functions should be closely monitored. This medication should be stored away from moisture and heat, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The storage temperature should ideally be maintained between 1 and 30 degrees Celsius. This helps to preserve the efficacy and safety of the medication for a long time.
Reddish-brown round film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Withus Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.